Question 1

Does UBS Group own CTOR stock?

Accepted Answer

Yes. As of its Q2 2026 13F, UBS Group holds 334,619 shares of CTOR (Citius Oncology), worth $217,502.

Question 2

How many shares of CTOR does UBS Group own?

Accepted Answer

As of its Q2 2026 13F, UBS Group holds 334,619 shares of CTOR (Citius Oncology).

Question 3

What is UBS Group's CTOR position worth?

Accepted Answer

As of its Q2 2026 13F, UBS Group's CTOR position is worth $217,502.

Question 4

Is UBS Group buying or selling CTOR?

Accepted Answer

In Q2 2026, UBS Group increased its CTOR position from 36,840 to 334,619 shares.

Question 5

When did UBS Group first buy CTOR?

Accepted Answer

UBS Group first reported CTOR in its Q3 2024 13F and has listed it in 8 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	334,619	+808.3%	$217,502	0.0%	$0.65	25
2026-Q1	Increased	36,840	+71.6%	$22,840	0.0%	$0.62	19
2025-Q4	Increased	21,464	+389x	$21,464	0.0%	$1.00	21
2025-Q3	Decreased	55	-99.6%	$112	0.0%	$2.03	0
2025-Q2	Decreased	15,423	-69.0%	$67,090	0.0%	$4.35	0
2025-Q1	Increased	49,745	+100.5%	$46,263	0.0%	$0.93	22
2024-Q4	Increased	24,805	+1419.9%	$28,526	0.0%	$1.15	21
2024-Q3	New	1,632	—	$2,268	0.0%	$1.39	18